Financière de Tubize SA Income
What is the Income of Financière de Tubize SA?
The Income of Financière de Tubize SA is €319.735M
What is the definition of Income?
Net income available for common shareholders equals net income minus preferred dividends paid.
ttm (trailing twelve months)
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
Income of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with income similar to Financière de Tubize SA
- Kayne Anderson Infrastructure Fund Inc has Income of $318.916M
- Aditya Birla Money has Income of ₨318.930M
- Xylem has Income of $319.000M
- Arvind SmartSpaces has Income of ₨319.159M
- Mercury General has Income of $319.197M
- Kothari Products has Income of ₨319.500M
- Financière de Tubize SA has Income of €319.735M
- RSA Insurance Plc has Income of £320.000M
- Aptargroup has Income of $320.209M
- ChampionX has Income of $320.401M
- Huami Corp has Income of ¥320.412M
- Dynavax Technologies has Income of $320.502M
- CoreLogic Inc has Income of $321.099M